An oncology pharmacist discusses how to manage neutropenic toxicity from treatment with CDK4/6 inhibitors for HR-positive breast cancer.
Kristina Frinzi Byers, PharmD, BCOP
Advertisement
Articles by Kristina Frinzi Byers, PharmD, BCOP
Advertisement
Latest Updated Articles
Management of Neutropenic Toxicity From CDK4/6 InhibitorsPublished: January 17th 2019 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: Key Anticipated Updates in Breast and Lung Tumors
2
Bridging Radiotherapy Prior to CAR T May Be Safe in R/R Multiple Myeloma
3
Anti-TIGIT Combination Therapy Yields Positive Survival in Gastric Cancers
4
Adjuvant Chemotherapy Improves Long-Term Survival in Endometrial Cancer
5
